Invetso Quality Score — BOLT

Bolt Biotherapeutics, Inc. · 3.4/10 — Weak · Updated September 2026

3.4Weak

Last updated: September 2026

Factor Snapshot

Durability🔴 Weak
Capital Efficiency🔴 Weak
Growth Quality🟡 Moderate
Risk Profile🟡 Moderate
Capital Allocation🟡 Moderate
Scalability🟡 Moderate

Invetso Quality Score

🔴 3.4 (Weak)

Core Drivers

No durable moat is evident: The provided inputs do not show defensible pricing power, customer lock-in, network effects, or efficient scale, so BOLT sits well behind global peers with structurally protected economics.

Capital is not compounding effectively: Deeply negative returns on capital are the dominant issue because they show that current investment is not translating into durable economic value, which is a major disadvantage versus stronger peers.

Liquidity and asset-light structure provide some resilience: Net cash, healthy near-term liquidity, and low capex reduce immediate balance-sheet stress and keep the company from looking distressed, which limits downside relative to weaker peers.

Key Constraints

Growth remains unproven at scale: The dataset does not verify a durable multi-year compounding record, and current spending intensity has not yet produced convincing revenue efficiency or operating leverage.

Risk is elevated by weak cash conversion quality: High leverage relative to equity, zero interest coverage, and opaque cash-generation quality leave the profile more fragile than cash-generative peers if operating conditions soften.

Synthesis

BOLT’s investment profile is defined more by what is missing than by what is working. The company has some resilience from net cash, liquidity, and low capex, but those strengths do not offset the absence of a durable moat or evidence that capital is compounding into attractive long-term returns. Relative to global peers, it looks lagging on economic quality because the business still lacks a proven advantage in pricing power, retention, or scale efficiency. The growth setup is not hopeless, but it remains execution-dependent rather than structurally supported, which keeps upside uncertain. At the same time, the downside is not purely balance-sheet driven, since weak capital efficiency and heavy spending intensity can continue to suppress quality even if revenue stabilizes. Overall, this is a low-quality profile with some financial flexibility, but not one that yet shows the durable, peer-leading characteristics associated with stronger long-term compounders.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Bolt Biotherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →